BioLASCO Taiwan Co., Ltd. (TPEX:6662)

Market Cap	870.81M
Revenue (ttm)	304.65M
Net Income (ttm)	44.91M
Shares Out	25.61M
EPS (ttm)	1.75
PE Ratio	19.43
Forward PE	n/a
Dividend	1.65 (4.85%)
Ex-Dividend Date	Jul 26, 2024

Volume	2,000
Average Volume	7,219
Open	34.00
Previous Close	34.00
Day's Range	34.00 - 34.00
52-Week Range	30.70 - 41.00
Beta	0.11
RSI	50.47
Earnings Date	Aug 4, 2025

About BioLASCO Taiwan

BioLASCO Taiwan Co., Ltd. provides bio-materials and surgical services in Taiwan and internationally. It breeds and produces SPF laboratory rats and mice, including outbreed stocks, inbreed strains, and immune deficient models, as well as offers special animal model services. The company also provides endotoxin detection, animal heath diagnostic, and serological kits, as well as biological indicators. In addition, it offers IVC systems and ventilated houses equipment; professional and automated animal watering systems; transponders; chlorine di...

• Industry: Biotechnology
• Sector: Healthcare
• Founded: 1990
• Employees: 91
• Stock Exchange: Taipei Exchange
• Ticker Symbol: 6662

Financial Performance

In 2024, BioLASCO Taiwan's revenue was 292.50 million, an increase of 10.49% compared to the previous year's 264.72 million. Earnings were 44.03 million, a decrease of -11.49%.